KYAN is a clinical stage technology company that currently has 3 novel combination therapies and 3 individualized regimens in clinical trials. Additional indications are under development and will progress towards clinical validation within the next year. With KYAN, drug development and individualized treatment is accelerated towards the clinic, implicitly de-risked, with efficacy and safety optimized.